GLAND

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2.6% on Friday after U.S. President Donald Trump announced a 100% tariff on branded and patented drugs, effective October 1.

All 20 constituents of the index were lower as of 9:30 a.m. IST. Heavyweight Sun Pharmaceutical Industries SUN.NS fell 3.4%.

The U.S. takes slightly more than a third of India’s drug exports, mostly cheaper generics, which rose 20% to about $10.5 billion in fiscal 2025.

The near term impact of the tariffs is likely to be limited, as India mainly exports generics, ICICI Securities research analyst Pankaj Pandey said in a note.

"That being said, uncertainty still remains whether complex generics and biosimilars will come under tariff embargo in the future," Pandey added.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee)

(([email protected];))

Aug 12 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES APPROVAL FROM USFDA FOR NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION

Further company coverage: GLAD.NS

(([email protected];;))

- Source link: (https://shorturl.at/7l96S)

- Note: Reuters has not verified this story and does not vouch for its accuracy

(Bengaluru newsroom)

(([email protected]; +91 80 6749 1310;))

July 11 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES GMP COMPLIANCE CERTIFICATE FROM DANISH AGENCY

• PASHAMYLARAM FACILITY RECEIVES GMP COMPLIANCE FROM DANISH MEDICINES AGENCY

Source text: ID:nNSE1q7sTy

Further company coverage: GLAD.NS

(([email protected];;))

** Gland Pharma's shares GLAD.NS up nearly 2% to 1,618 rupees

** Co gets approval from U.S. Food and Drug Administration for "Angiotensin II Acetate Injection" that would help increase blood pressure in adults

** Eligible for 180 days of generic drug exclusivity - co

** Analysts, on avg, rate GLAD "hold", median PT 1,575 rupees - data compiled by LSEG

** Day's move cuts stock's YTD decline to 9%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

** Indian pharma companies .NIPHARM climb 1.7%, the most among 13 major sectors

** Nineteen of 20 stocks on index trading higher, with Gland Pharma GLAD.NS leading gains with 4% jump

** U.S. Department of Health and Human Services (HHS) says it expects every drugmaker to align U.S. prices for branded drugs, without generic or biosimilar competition, with the lowest prices in peer countries

** "The HHS order provides relief to generic drugmakers as it talks about price cuts only for branded drugs, indicating that generics will most likely not be affected," Shrikant Akolkar, analyst at Nuvama, says

** Mehul Shah, analyst at HDFC Securities, says order "big relief" especially for biosimilars and generic drug makers

** Cipla CIPL.NS, Dr Reddy's REDY.NS, Sun Pharma SUN.NS up ~2% each; Biocon BION.NS adds 1.6%

** Pharma stocks fell 2% on May 12 after Donald Trump signed order to cut prescription drug prices

(Reporting by Kashish Tandon and Vivek Kumar M in Bengaluru)

(([email protected]))

** Pharmaceutical stocks slide 1.8% after U.S. President Donald Trump signals "major" tariff on pharma imports soon

** Nifty Pharma .NIPHARM index down 6.3% since April 4 when Trump first threatened the duties, ending the sector's brief reprieve

** According to Trump, the pharma duty will incentivise drug cos to move operations to the U.S.

** NIPHARM's all 20 constituents in the red; Gland Pharma GLAD.NS, Dr Reddy's Laboratories REDY.NS, Lupin LUPN.NS, IPCA Laboratories IPCA.NS lose between 2%-4.3%

** Sub-index extends YTD losses to 14.4% vs Nifty 50's .NSEI 5.1% fall

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

April 3 (Reuters) - Shares of Indian drugmakers surged 4% on Thursday, in contrast to the drop in the broader stock market, after U.S. President Donald Trump's administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs.

The pharma sub-index .NIPHARM was the only one among the 13 major sectors that was trading higher. The benchmark Nifty 50 .NSEI was down 0.74%.

Trump imposed a 26% reciprocal tariff on Indian imports as part of his wider plan to impose a 10% baseline tariff on all imports from April 5, but the duties do not apply to certain goods, including pharmaceuticals.

The U.S. imports nearly a third of Indian pharma products sold overseas. India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.

On the day, Dr Reddy's REDY.NS climbed 6% and was the top gainer on the benchmark Nifty 50 index. Gland Pharma GLAD.NS surged 12% and was the top gainer among pharma stocks.

Cipla CIPL.NS and Sun Pharma SUN.NS rose 4% each.

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Gland Pharma GLAD.NS rises 2.4% to 1,622.85 rupees

** Global investor Vanguard's two funds buy ~1.9 mln shares, aggregating to 1.13% stake in the drug maker at 1,588.69 rupees, NSE data shows

** GLAD top gainer on pharma index .NIPHARM, which is trading flat

** Stock down 9% YTD vs NIPHARM's 7.7% decline

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Indian equities set for inflows of up to $1.4 billion on Friday as FTSE March semi-annual rebalancing to come into effect, per analysts

** ICICI Bank ICBK.NS will be the biggest beneficiary, to see inflows worth $426.9 million from weight increases by FTSE, MSCI and BSE, says IIFL

** Large inflows in ICBK due to merger between bank and ICICI Securities ICCI.NS, whose shares will trade for the last time on Friday

** ICCI shareholders to get 67 ICBK shares per 100 shares of ICCI

** Kotak Mahindra Bank KTKM.NS to see $146 million inflows as FTSE increases weight, says Nuvama

** FTSE adds 360 ONE WAM ONEW.NS, Bajaj Housing Finance BAJO.NS, BSE BSEL.NS and other stocks to FTSE All World Index

** Stocks that might see inflows due to FTSE rebalancing include Zomato ZOMT.NS, ITC Hotels ITCT.NS, Gland Pharma GLAD.NS and BAJO

(Reporting by Vivek Kumar M)

(([email protected];))

Feb 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - CONCLUSION OF US FDA INSPECTION AT COMPANY’S JNPC FACILITY, VISAKHAPATNAM

• GLAND PHARMA - INSPECTION WAS CONCLUDED WITH THREE FORM 483 OBSERVATIONS

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

** Shares of Gland Pharma GLAD.NS fall ~3.3% to 1462.8 rupees

** Co's Q3 revenue falls 10.4% on production setbacks at French unit Cenexi's site near Paris

** Cenexi sales down due to regulatory inspections, breakeven now pushed back by a year vs Q3 target

** Jefferies says Cenexi "continued to bleed" and India and US saw the biggest sales disappointment in Q3

** InCred Equities cuts to 'sell' from 'hold' on "repeated delays in Cenexi's turnaround"

** Citi retains 'sell' on GLAD's inablity to optimize its 'world class' injectables manufacturing set-up

** 10 analysts avg rating is 'hold', avg PT is 1671 rupees, implying ~13.5% upside to current price -LSEG data

** Including session's decline, stock down 27% in last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Feb 3 (Reuters) - Gland Pharma Ltd GLAD.NS:

• Q3 CONSOL NET PROFIT 2.05 BILLION RUPEES; IBES EST. 2.04 BILLION RUPEES

• Q3 CONSOL REVENUE FROM OPERATIONS 13.84 BILLION RUPEES; IBES EST. 15.69 BILLION RUPEES

Further company coverage: GLAD.NS

(([email protected];))

Jan 16 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVED ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR DUNDIGAL FACILITY

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];;))

Jan 15 (Reuters) - Gland Pharma Ltd GLAD.NS:

• SHYAMAKANT GIRI WILL ASSUME THE OFFICE OF CHIEF EXECUTIVE OFFICER

Further company coverage: GLAD.NS

(([email protected];;))

Dec 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - ANSM INSPECTION AT CENEXI'S FONTENAY MANUFACTURING FACILITY

• GLAND PHARMA LTD - CENEXI'S FONTENAY FACILITY RECEIVES 10 OBSERVATIONS FROM ANSM

Source text: ID:nBSEbCwXW2

Further company coverage: GLAD.NS

(([email protected];))

** Shares of generic injectables maker Gland Pharma GLAD.NS rise 2% to 1,810 rupees in early trade

** Stock among top gainers on Nifty Pharma index .NIPHARM which is up 0.19%

** Co gets approval from U.S. FDA for phytonadione injectable emulsion, which is used to treat coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity

** Co expects to launch the drug in the near future

** Avg rating on stock is a "hold," among 10 stocks on pharma index with this rating; median PT is 1,800 rupees - LSEG data

** Day's gains erase weekly loss, stock now up 2% this week

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))

Dec 3 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIPT OF US FDA APPROVAL FOR LATANOPROST OPHTHALMIC SOLUTION, 0.005%

• EXPECTS TO LAUNCH THIS PRODUCT THROUGH ITS MARKETING PARTNERS IN FY25

Source text: ID:nNSE85dvSv

Further company coverage: GLAD.NS

(([email protected];;))

** Gland Pharma Ltd GLAD.NS shares jump nearly 10% to 1,770 rupees, set for their best day since August 2023

** Kotak Institutional Equities upgrades drugmaker's stock to "reduce" from "sell"; stock saw a 24% slump over the last three months

** Brokerage says GLAD's Q2 earnings show slump has likely bottomed out, sees sales growth for core business and French unit Cenexi recovering gradually

** Kotak's PT of 1,625 rupees is second-highest among analysts tracking stock - LSEG data

** Investec, Motilal Oswal retain "buy"; Motilal sees earnings growing 20% CAGR between FY25-27 after two years of decline

** Around 2.7 mln shares traded, 11x stock's 30-day avg volume

** Analysts tracking GLAD rate it "hold" on avg - LSEG data

** Stock trims YTD losses to 5.7% but trails Nifty Pharma Index's .NIPHARM 34% jump YTD

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Nov 4 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA Q2 CONSOL NET PROFIT 1.64 BILLION RUPEES; IBES EST. 1.6 BILLION RUPEES

• GLAND PHARMA Q2 CONSOL REVENUE FROM OPERATIONS 14.06 BILLION RUPEES; IBES EST. 14.2 BILLION RUPEES

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];;))

Oct 18 (Reuters) - Gland Pharma Ltd GLAD.NS:

• NAMES SHYAMAKANT GIRI AS CEO

Source text for Eikon: ID:nBSE7vHkpc

Further company coverage: GLAD.NS

(([email protected];;))

** Shares of Gland Pharma GLAD.NS tumble as much as 9%, before pulling back to a 4% drop

** Injectables manufacturer posted a surprise drop in Q1 profit

** Ambit Capital says in the acquired Cenexi business, growth and margin trajectory was better than its core business, but recovery to be gradual

** Says increasing rev share from lower-margin, non-US markets, slow-margin recovery in Cenexi to continue capping margins

** Analysts avg rating on GLAD is equivalent of "hold" and median PT is 1,913.5 rupees -LSEG data

** Stock is only loser on the Nifty pharma index on the day, which is up 1.3%

** GLAD cuts YTD gains to 5%, while the pharma index has gained about 11.5%

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Aug 6 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA Q1 CONSOL NET PROFIT 1.44 BILLION RUPEES; IBES PROFIT EST. 2.09 BILLION RUPEES

• GLAND PHARMA Q1 CONSOL REVENUE FROM OPERATIONS 14.02 BILLION RUPEES; IBES EST. 14.95 BILLION RUPEES

Source text for Eikon: ID:nBSE2GZXf7

Further company coverage: GLAD.NS

(([email protected];))

July 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• CONCLUSION OF US FDA SURPRISE INSPECTION AT DUNDIGAL FACILITY, HYDERABAD

• INSPECTION CONCLUDED WITH TWO 483 OBSERVATIONS

• OBSERVATIONS ARE PROCEDURAL IN NATURE

Source text for Eikon: ID:nNSE6jkd57

Further company coverage: GLAD.NS

(([email protected];;))

July 23 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GETS TENTATIVE APPROVAL FROM USFDA FOR LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION

• UPON FINAL APPROVAL, CO MAY BE ELIGIBLE FOR 180 DAYS OF GENERIC DRUG EXCLUSIVITY

Source text for Eikon: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

** Shares of generic injectables maker Gland Pharma GLAD.NS fall as much as 3.5% to 1,776 rupees; last down 1.3%

** Fosun Pharma Industrial to pare 5% stake in GLAD through block deals for about $172 mln, according to reports

** Fosun, owned by China's Shanghai Fosun Pharmaceutical Group 600196.SS, will sell shares at a 4.9% discount to last closing price, reports add

** GLAD on track for sixth straight session of losses

** Stock among top losers on Nifty Pharma Index .NIPHARM, which is up 0.2%

** Busiest session for GLAD since May 2023 after the stock beat fourth-qtr rev estimates; trading vols. at about 1.1 mln shares, nearly four times the 30-day avg.

** Twelve analysts, on average, rate stock "hold", with median PT of 1,872.50 rupees - LSEG data

** Stock down ~6% YTD vs. an ~18% rise in Nifty pharma index

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

June 18 (Reuters) -

• FOSUN IS SAID TO PLAN BLOCK DEALS TO PARE 6% STAKE IN GLAND PHARMA - BLOOMBERG NEWS

Source text: [https://tinyurl.com/4dw5kfer]

Further company coverage: 600196.SS

(([email protected];))

June 7 (Reuters) - Gland Pharma Ltd GLAD.NS:

• APPOINTMENT OF SRINIVAS SADU AS CEO

• APPOINTMENT OF SRINIVAS SADU AS EXECUTIVE CHAIRMAN

• TAKEN ON RECORD COMPLETION OF TENURE OF CHAIRMAN YIU KWAN STANLEY LAU

Further company coverage: GLAD.NS

(([email protected];;))

** Shares of Gland Pharma GLAD.NS rise as much as 2.5% before trimming some gains; last up 1.2% at 1,903 rupees

** Generic injectables maker said the U.S. FDA completed inspection at co's Visakhapatnam facility with zero 483 observations

** Stock was down ~1% before the announcement

** GLAD is second-biggest gainer on the Nifty pharma index .NIPHARM - down 0.1%

** Analysts' avg rating on stock is "Hold", in line with rival Dr. Reddy's REDY.NS while Cipla CIPL.NS is rated "Buy" - LSEG

** Median PT on GLAD is 1,872.5 rupees

** Including session's gains, GLAD is up ~20% YTD vs 14% surge in NIPHARM

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of Gland Pharma GLAD.NS up 4.5% at 1,873.8 rupees, on track for best day since April 8

** Co's Q4 rev beat estimates but profit fell short

** Jefferies says GLAD's base business EBITDA margin expansion driven by core U.S. sales growth of 8% QoQ on new launches and favourable pricing

** Brokerage adds, base business margin profile is showing continued improvement but acquisition of Cenexi is taking longer than expected to show results

** Rival Dr Reddy's REDY.NS beat Q4 profit estimates, Cipla CIPL.NS and Sun Pharma SUN.NS both missed rev estimates

** GLAD, REDY rated "hold" on avg; CIPL and SUN rated "buy" - LSEG data

** YTD, GLAD down 1.5%; REDY, CIPL and SUN up between 1.2% and 19%

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))